MariMed Inc. (MRMD) Stock Price & Analysis
MariMed Inc. (MRMD) — price $0.049 (-10.91%), as of the Nov 19, 2026 trading session; market cap $19.9M.
Educational signal · not a buy or sell recommendation · How to read this
MariMed Inc. · MRMD
MariMed Inc. is a prominent player in the cannabis industry, focusing on the cultivation and sale of medicinal and adult-use cannabis products.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.049 | |
| Change on the day | -10.91% | |
| Market capitalisation | $19.9M | — |
| Shares traded on the day | 263.0K |
Price & events
Other perspectives
Council score for MariMed (MRMD): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is MariMed (MRMD), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. MariMed Inc. (MRMD) is the company analyzed here. It employs 808 people. In Q2 FY2026 it reported revenue of $42M and net income of -$4M. The market values it at $19.9M.
What do the latest results show for MariMed (MRMD)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $42M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $42M | -$4M | -$0.01 (diluted) |
| Q1 FY2026 | $39M | -$4M | -$0.01 (diluted) |
| Q4 FY2025 | $42M | -$5M | -$0.01 (diluted) |
| Q3 FY2025 | $41M | -$3M | -$0.01 (diluted) |
What are the financial strengths and risks for MariMed (MRMD)?
Short answer · as of
The distress and quality screens read Altman Z -0.11 · Piotroski F 4. Trailing ratios: ROE -29.7% · ROA -7.6% · current ratio 0.92 · earnings yield -49.8% · free-cash-flow yield 27.2%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -0.11 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-29.7%) — the business is not currently generating profit on shareholder capital.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MRMD in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported MRMD in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About MRMD
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
Is MRMD a good stock to buy?
Stock Expert AI does not rate MRMD buy, sell or hold. MariMed Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the MRMD stock price today?
The last price recorded for MariMed Inc. (MRMD), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for MRMD?
Evaluate MRMD on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does MRMD data refresh on this page?
MRMD's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven MRMD's recent stock price performance?
MariMed Inc. (MRMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio catering to various consumer needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MRMD overvalued or undervalued right now?
MariMed Inc. (MRMD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MRMD before investing?
Before investing in MariMed Inc. (MRMD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding MRMD to a portfolio?
Key strength of MariMed Inc. (MRMD): Diverse product portfolio catering to various consumer needs. Weigh rewards against risks and diversify. Not financial advice.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 8 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com